Skip to main content

healthcare stocks

3 articles found

UNH Analysis: UnitedHealth's $263 Billion Healthcare Empire Has Lost Half Its Value — Why the Largest US Insurer's Margin Collapse Makes It Either a Value Trap or a Generational Buy

UnitedHealth Group (NYSE: UNH) has fallen 52% from its 52-week high of $606.36 to trade at $290, erasing roughly $280 billion in market capitalization in the process. The largest health insurer in the United States — which covers more than 50 million people through its UnitedHealthcare division and operates the massive Optum health services platform — closed out 2025 with a catastrophic fourth quarter that saw net income collapse to virtually zero. The stock now trades at 21.9x trailing earnings with a market cap of $263 billion, down from a premium north of 30x just twelve months ago. Full-year 2025 revenue came in at approximately $447.6 billion, making UNH one of the highest-revenue companies in the world, but net income fell to $12.1 billion from $15.2 billion in 2024 and $22.4 billion in 2023. The trajectory is unmistakable: medical costs are rising faster than premiums, and the managed care giant's operating margins have compressed from 8.3% in Q1 to just 0.3% in Q4. For investors, UNH presents a stark binary: either this is a cyclical margin trough in a business with durable competitive advantages and the stock is cheap, or rising healthcare utilization and regulatory headwinds signal a structural deterioration that the market has not yet fully priced in. The data below lays out both cases.

UNH stock analysisUnitedHealth Groupmanaged care stocks

LLY Analysis: Eli Lilly's $952 Billion Pharma Empire Delivers 85% Gross Margins and $21 Billion in Net Income — Why the GLP-1 Pioneer Still Commands a 44x Multiple

Eli Lilly and Company (NYSE: LLY) has transformed from a traditional pharmaceutical giant into the undisputed leader of the weight loss drug revolution. Trading at $1,009.52, the Indianapolis-based company commands a $952 billion market capitalization — making it the most valuable pharmaceutical company in the world. With full-year 2025 revenue of $65.2 billion and net income of $20.6 billion, Lilly's financial trajectory has been nothing short of extraordinary. The story behind Lilly's meteoric rise centers on two blockbuster GLP-1 receptor agonist drugs: Mounjaro (tirzepatide) for type 2 diabetes and Zepbound for chronic weight management. These medications have generated unprecedented demand, propelling quarterly revenue from $12.7 billion in Q1 2025 to $19.3 billion in Q4 2025 — a 52% sequential acceleration in a single year. The stock sits 11% below its 52-week high of $1,133.95 but has surged 62% from its 52-week low of $623.78, reflecting both the massive opportunity ahead and the premium valuation investors are willing to pay. Beyond weight loss, Lilly continues to expand its pipeline across immunology, oncology, and neuroscience. Recent Phase 3 data showed Omvoh achieving over 90% steroid-free remission in Crohn's disease patients at three years — a landmark result that opens another multi-billion-dollar market. For investors, the central question is whether Lilly's growth trajectory justifies paying nearly 44 times earnings for a pharma stock.

LLY stock analysisEli Lilly stockGLP-1 drugs

JNJ Analysis: At a 52-Week High and Reshaping Its Portfolio — Why Johnson & Johnson's Best Days May Still Be Ahead

Johnson & Johnson is trading at $246.61, within touching distance of its 52-week high of $246.88 and a staggering 74% above its 52-week low of $141.50. That kind of run from a $594 billion healthcare giant isn't supposed to happen — and yet here we are, watching one of the most defensive names in the market act like a growth stock. The catalyst isn't a single product launch or earnings beat. It's a wholesale reshaping of what JNJ actually is. Today's news that the company is exploring a $20 billion sale of its orthopedics unit, combined with a $1 billion investment in cell therapy manufacturing in Pennsylvania, tells you everything about where management is taking this business: away from commoditized medical devices and toward the high-margin frontier of biologics and cell-based therapies. For investors who bought the Kenvue spinoff dip below $150, the returns have been exceptional. The question now is whether JNJ at 22x earnings still offers value, or whether the portfolio transformation is already priced in.

Johnson & JohnsonJNJstock analysis